Levels of Vascular Endothelial Growth Factor Are Elevated in the Vitreous of Patients with Subretinal Neovascularisation

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 1996 Apr 1

PMID 8703891

Citations 42

Authors

J A Wells

R Murthy

R Chibber

A Nunn

P A Molinatti

E M Kohner

Z J Gregor

Affiliations

Soon will be listed here.

Abstract

Background: Vascular endothelial growth factor (VEGF) has been shown to play a major role in intraocular neovascularisation in ischaemic retinal diseases. Subretinal neovascularisation is an important cause of central visual loss, but little is known about the role of this growth factor in its pathogenesis. The aim of this study was to investigate the possible role of VEGF in the development of subretinal neovascularisation.

Methods: Undiluted vitreous samples were obtained from patients undergoing vitrectomy for removal of non-age-related subfoveal neovascular membranes (SFNM). For comparison vitreous from patients undergoing vitrectomy for idiopathic full thickness macular holes (FTMH) and proliferative diabetic retinopathy (PDR) was used. Indirect enzyme linked immunosorbent assay (ELISA), with an antibody directed against the conserved N-terminal region of human VEGF165, was used to determine vitreous levels of VEGF. The growth factor was also localised in the vitreous of patients with SFNM by western blot analysis.

Results: The mean (SE) VEGF concentration in the vitreous of patients with SFNM was 27.78 (2.22) ng/ml (n = 8), FTMH was 16.62 (0.9) ng/ml (n = 18), and PDR was 37.77 (3.28) ng/ml (n = 16). The differences between the PDR group and SFNM group versus the FTMH group were both significant (p = 0.0001 and p = 0.0015) as analysed by the Wilcoxon rank sum test).

Conclusions: Vitreous levels of VEGF are significantly elevated in eyes with non-age-related subretinal neovascularisation compared with eyes with FTMH but not as elevated as in PDR. This suggests that VEGF is involved in subretinal angiogenesis.

Citing Articles

Resveratrol, an Inhibitor Binding to VEGF, Restores the Pathology of Abnormal Angiogenesis in Retinopathy of Prematurity (ROP) in Mice: Application by Intravitreal and Topical Instillation.

Hu W, Zhang X, Leung K, Duan R, Dong T, Qin Q Int J Mol Sci. 2022; 23(12).

PMID: 35742898 PMC: 9223486. DOI: 10.3390/ijms23126455.

Central Role of Oxidative Stress in Age-Related Macular Degeneration: Evidence from a Review of the Molecular Mechanisms and Animal Models.

Abokyi S, To C, Lam T, Tse D Oxid Med Cell Longev. 2020; 2020:7901270.

PMID: 32104539 PMC: 7035553. DOI: 10.1155/2020/7901270.

Oleanolic Acids Inhibit Vascular Endothelial Growth Factor Receptor 2 Signaling in Endothelial Cells: Implication for Anti-Angiogenic Therapy.

Lee D, Lee J, Jeon J, Kim K, Yun J, Jeong H Mol Cells. 2018; 41(8):771-780.

PMID: 30037214 PMC: 6125422. DOI: 10.14348/molcells.2018.0207.

Bevacizumab Injection in Patients with Neovascular Age-Related Macular Degeneration Increases Angiogenic Biomarkers.

Cabral T, Lima L, Mello L, Polido J, Correa E, Oshima A Ophthalmol Retina. 2018; 2(1):31-37.

PMID: 29376143 PMC: 5783314. DOI: 10.1016/j.oret.2017.04.004.

Quercetin Mitigates Inflammatory Responses Induced by Vascular Endothelial Growth Factor in Mouse Retinal Photoreceptor Cells through Suppression of Nuclear Factor Kappa B.

Lee M, Yun S, Lee H, Yang J Int J Mol Sci. 2017; 18(11).

PMID: 29165402 PMC: 5713462. DOI: 10.3390/ijms18112497.

References

Senger D, Galli S, Dvorak A, Perruzzi C, Harvey V, Dvorak H . Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983; 219(4587):983-5. DOI: 10.1126/science.6823562. View

Senger D, Perruzzi C, Feder J, Dvorak H . A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986; 46(11):5629-32. View

Hoshino S, Miyazawa H, Enomoto T, Hanaoka F, Kikuchi Y, Kikuchi A . A human homologue of the yeast GST1 gene codes for a GTP-binding protein and is expressed in a proliferation-dependent manner in mammalian cells. EMBO J. 1989; 8(12):3807-14. PMC: 402068. DOI: 10.1002/j.1460-2075.1989.tb08558.x. View

Keck P, Hauser S, Krivi G, Sanzo K, Warren T, Feder J . Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246(4935):1309-12. DOI: 10.1126/science.2479987. View

Grossniklaus H, Martinez J, Brown V, Lambert H, Sternberg Jr P, Capone Jr A . Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1992; 114(4):464-72. DOI: 10.1016/s0002-9394(14)71859-8. View

Shweiki D, Itin A, Soffer D, Keshet E . Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359(6398):843-5. DOI: 10.1038/359843a0. View

Adamis A, Shima D, Yeo K, Yeo T, Brown L, Berse B . Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun. 1993; 193(2):631-8. DOI: 10.1006/bbrc.1993.1671. View

Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O . Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994; 269(9):6271-4. View

GASS J . Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol. 1994; 118(3):285-98. View

10.

Adamis A, Miller J, Bernal M, DAmico D, Folkman J, Yeo T . Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994; 118(4):445-50. DOI: 10.1016/s0002-9394(14)75794-0. View

11.

Aiello L, Avery R, Arrigg P, Keyt B, Jampel H, Shah S . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22):1480-7. DOI: 10.1056/NEJM199412013312203. View

12.

Malecaze F, Clamens S, Mathis A, Chollet P, Favard C, Bayard F . Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol. 1994; 112(11):1476-82. DOI: 10.1001/archopht.1994.01090230090028. View

13.

Dvorak H, Detmar M, Claffey K, Nagy J, Van de Water L, Senger D . Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol. 1995; 107(1-3):233-5. DOI: 10.1159/000236988. View

14.

Saxe S, Grossniklaus H, Lopez P, Lambert H, Sternberg Jr P, LHernault N . Ultrastructural features of surgically excised subretinal neovascular membranes in the ocular histoplasmosis syndrome. Arch Ophthalmol. 1993; 111(1):88-95. DOI: 10.1001/archopht.1993.01090010092033. View